Genmab A (GMAB) Non Operating Income (2018 - 2026)
Genmab A's (GMAB) quarterly Non Operating Income came in at -$106.0 million in Q1 2026, down 289.29% YoY from $56.0 million in Q1 2025, and down 174.65% on a QoQ basis from $142.0 million in Q3 2025.
Genmab A (GMAB) Non Operating Income (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Non Operating Income data on file, last reported at -$106.0 million in Q1 2026.
- Quarterly Non Operating Income fell 289.29% year-over-year to -$106.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $239.0 million (down 80.54% YoY) and the FY2025 annual result came in at $139.0 million, down 60.73% from the prior year.
- Non Operating Income retreated to -$106.0 million in Q1 2026, from $142.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $147.0 million in Q3 2024 to a low of -$106.0 million in Q1 2026.
- A 3-year average of $74.4 million and a median of $133.0 million in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2025 — Non Operating Income dropped 3.4% — and 2026, when it slumped 289.29%.
- Tracing GMAB's Non Operating Income over 3 years: stood at $147.0 million in 2024, then declined by 3.4% to $142.0 million in 2025, then sank by 174.65% to -$106.0 million in 2026.
- The last three Non Operating Income figures came in at -$106.0 million (Q1 2026), $142.0 million (Q3 2025), and $56.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -106.00 Mn |
| Sep 30, 2025 | 142.00 Mn |
| Mar 31, 2025 | 56.00 Mn |
| Sep 30, 2024 | 147.00 Mn |
| Mar 31, 2024 | 133.00 Mn |
| Mar 31, 2021 | 892.00 Mn |
| Sep 30, 2020 | -187.00 |
| Mar 31, 2020 | 283.00 Mn |
| Dec 31, 2019 | 348.00 |
| Sep 30, 2019 | 348.55 Mn |
| Dec 31, 2018 | 30.43 Mn |